BERLIN, Germany and SEATTLE, May 11, 2006 (PRIMEZONE) -- The German biotech company Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX) announced today that the company will be presenting at the 3rd Annual Rodman & Renshaw Global Healthcare Conference in Monte Carlo, on Tuesday May 16, 2006, at 3.20 p.m. local time, at the The Le Meridien Sea Club. Alexander Olek, Ph.D., Chief Executive Officer of Epigenomics AG, will give a review of the company and update the audience on current business developments. The webcast of the presentation will be available on the Internet at http://wsw.com/webcast/rrshq8/epigenomics/ .
About Epigenomics
Epigenomics is a molecular diagnostic company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.